| Customization: | Available |
|---|---|
| CAS No.: | 74150-27-9 |
| Formula: | C19h18n4o2 |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Pimobendan |
| CAS number | 74150-27-9 |
| Molecular formula | C19H18N4O2 |
| Molecular weight | 334.37 |
| Appearance | White to beige Powder |
| Purity | 99.0% |
| Packge | 10gram,100gram,1KG or under requirement |
| Description | Pimobendan, a novel cardiotonic vasodilator, was introduced in Japan for the treatment of acute and mild to moderate chronic heart failure. It is a phosphodiesterase inhibitor and is able to enhance sensitization of myocardial contractile regulatory protein to calcium ions. The combination of these effects contribute to its inotropic activity. In patients with severe congestive heart failure, orally administered pimobendan improves cardiac index, stroke volume index, pulmonary wedge pressure, and systemic and pulmonary vascular resistance. Pimobendan is reported to be well tolerated and largely devoid of the proarrhythmic effects of classical phosphodiesterase Ill inhibitors. Studies also suggested that combination of the inotropic agent pimobendan with an ACE inhibitor such as enalapril may be superior to monotherapy for heart failure patients. |
Pimobendan is a cardiotonic agent. The study of the cardiotonic mechanism of pimobendan using ventricular muscles from rabbits and guinea pigs suggests that Pimobendan acts by inhibiting phosphodiesterase III and potassium channel. The potent venodilating action of pimobendan makes it a suitable treatment option for patients with congestive heart failure (CHF) as it also improves systemic vasoconstriction
Pimobendan is mainly used in the management of heart failure in dogs, most commonly caused by myxomatous mitral valve desease (also previously known as endocardiosis), ordilated cardiomyopathy.
){kind=link}